Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Pardes Biosciences's share price for the quarter that ended in Jun. 2023 was $1.81. Pardes Biosciences's Shares Outstanding (EOP) for the quarter that ended in Jun. 2023 was 60.40 Mil. Therefore, Pardes Biosciences's market cap for the quarter that ended in Jun. 2023 was $109.32 Mil.
Pardes Biosciences's quarterly market cap
declined
from Dec. 2022 ($100.63 Mil) to Mar. 2023 ($81.47 Mil) but then
increased
from Mar. 2023 ($81.47 Mil) to Jun. 2023 ($109.32 Mil).
Pardes Biosciences's annual market cap
increased
from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($929.25 Mil) but then
declined
from Dec. 2021 ($929.25 Mil) to Dec. 2022 ($100.63 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Pardes Biosciences's Enterprise Value for Today is $-19.25 Mil.
Pardes Biosciences Market Cap Historical Data
The historical data trend for Pardes Biosciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pardes Biosciences's Market Cap
For the Biotechnology subindustry, Pardes Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pardes Biosciences's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pardes Biosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Pardes Biosciences's Market Cap falls into.
Pardes Biosciences Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Pardes Biosciences's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pardes Biosciences (NAS:PRDS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Pardes Biosciences Market Cap Related Terms
Thank you for viewing the detailed overview of Pardes Biosciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Pardes Biosciences (Pardes Biosciences) Business Description
Pardes Biosciences Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel oral-antiviral therapeutics to improve the lives of patients suffering from life-threatening disease, starting with the lead product candidate, pomotrelvir (formerly known as PBI-0451), which is in clinical development and intended to treat COVID-19 in adult and pediatric patients. COVID-19 is caused by infection with the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Pomotrelvir inhibits the main coronaviral cysteine protease, a viral protein essential for the replication of all known coronaviruses, including SARS-CoV-2.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRDS has been successfully added to your 